Vitamin D and osteoporosis in chronic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Orthopedics

Background:

• Osteoporotic fractures are prevalent in chronic kidney disease (CKD) patients.
• CKD patients with fractures face higher morbidity and mortality rates compared to the general population.
• Vitamin D deficiency is common in CKD, exacerbated by proteinuria leading to nutrient loss.

Purpose of the Study:

• To highlight the importance of bone mineral density assessment for fracture prediction across all stages of CKD.
• To emphasize the need for early vitamin D supplementation in renal disease management.
• To provide recommendations for vitamin D treatment and prevention in CKD patients.

Main Methods:

• Review of current literature on CKD, osteoporosis, and vitamin D metabolism.
• Analysis of fracture risk factors and prediction in CKD.
• Evaluation of vitamin D deficiency prevalence and management strategies in CKD.

Main Results:

• Bone mineral density assessment is valuable for fracture prediction in CKD patients, especially when influencing treatment decisions.
• Proteinuria in CKD patients contributes to vitamin D deficiency through the loss of 25-hydroxyvitamin D and its binding protein.
• Cholecalciferol at 800 IU/day or equivalent monthly dosage is recommended for vitamin D deficiency treatment and prevention in CKD, mirroring general population guidelines.

Conclusions:

• Integrating bone mineral density assessment into CKD care can improve fracture risk management.
• Proactive vitamin D supplementation is essential for mitigating complications in CKD patients.
• Standard vitamin D supplementation protocols are effective for CKD patients, similar to the general population.